Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
ID: RFA-TR-23-017Type: BOTH
Overview

Topic

Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2024

Topic Link

https://www.sbir.gov/node/2486919

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-017.html
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through their SBIR program. The goal of this funding opportunity is to support the development of benchtop, portable, automated systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be easy to use, have integrated in-line sensors, and be capable of rapid and reproducible high-throughput analysis. The system should also be capable of maintaining culture without external intervention and be remotely monitored through real-time biosensing. The fabrication procedure must be cost-effective, mass producible, and robust. The funding opportunity is open for Phase I, Phase II, Fast-Track, and Direct to Phase II grant applications. The project duration is from 2024 to 2026, with multiple application due dates. More details can be found on the grants.gov website.

    Files
    No associated files provided.
    Similar Opportunities
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through their SBIR program. The goal of this funding opportunity is to support the development of benchtop, portable, automated systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be easy to use, have integrated sensors, and enable rapid and reproducible high-throughput analysis. The project should also focus on automation and miniaturization, with the potential for remote monitoring and real-time biosensing. The funding opportunity is open for Phase I, Phase II, Fast-Track, and Direct to Phase II grant applications. The project duration spans multiple years, with application due dates in February of each year. More information can be found on the grants.gov website.
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through a Small Business Technology Transfer (STTR) program. The goal of this funding opportunity is to support the development of bench top, portable, automated, self-contained systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be able to automate tissue preculture and loading, system operation, perfusion systems, and cell culture conditions. It should also include in-line sensors for monitoring and sensing, as well as software for instrument control and data processing. The system should be cost-effective, mass producible, and robust. The performance of the system should be characterized and validated, and the applicant should propose quantitative metrics for evaluating progress. The long-term goal is to achieve technological advances that enable the routine use of tissue chips in safety and efficacy assessment of therapeutics. The funding opportunity is open for Phase I, Phase II, and Fast-Track grant applications, with a project duration of up to 2 years. The application due dates are February 22, 2024, February 24, 2025, and February 23, 2026. More information can be found on the grants.gov website.
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through a Small Business Technology Transfer (STTR) program. The goal of this funding opportunity is to support the development of bench top, portable, automated, self-contained systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be able to automate tissue preculture and loading, system operation, perfusion systems, and cell culture conditions. It should also include in-line sensors for monitoring and sensing, as well as software for instrument control and data processing. The system should be cost-effective, mass producible, and robust. The performance of the system should be characterized and validated, and the applicant should propose quantitative metrics for evaluation. The long-term goal is to achieve technological advances that enable the routine use of tissue chips in safety and efficacy assessment of therapeutics. The funding opportunity is open for Phase I, Phase II, and Fast-Track grant applications, with a project duration of up to 2 years. The application due dates are February 22, 2024, February 24, 2025, and February 23, 2026. More information can be found on the grants.gov website.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that play a role in intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as large-scale production and manufacturing of EVs for therapeutic use. The funding opportunity is open to small business concerns and offers both Phase I and Phase II grants. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The development of IND enabling therapeutic platforms that can work towards regulatory approval and commercialization is prioritized. Applications must include project milestones and should align with the goals of the funding opportunity. The application due dates are June 6th of each year from 2023 to 2025. For more information, visit the solicitation agency URL: link.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field and advance the translation of EVs into clinical applications. The funding opportunity is open to small business concerns and offers both Phase I and Phase II grants. The projects should focus on large-scale GMP grade production and manufacturing challenges associated with the use of EVs as therapeutics. The application due dates are June 6th of each year from 2023 to 2025. For more information and to apply, visit the solicitation agency URL: link.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as the production of sufficient quantities of EVs, labor-intensive isolation procedures, and non-specific isolation methodologies. The funding opportunity is open for both Phase I and Phase II (Fast track) grant applications. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The funding opportunity prioritizes IND enabling therapeutic platforms that have the potential for regulatory approval and commercialization. Applicants are encouraged to engage with regulatory authorities and address the expected commercial impact of their proposed technology platform. The application due dates are June 6, 2023, June 6, 2024, and June 6, 2025. For more information, visit the solicitation agency URL: link.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as the production of sufficient quantities of EVs, labor-intensive isolation procedures, and non-specific isolation methodologies. The funding opportunity is open for both Phase I and Phase II (Fast track) grant applications. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The funding opportunity prioritizes IND enabling therapeutic platforms that have the potential for regulatory approval and commercialization. Applicants are encouraged to engage with the FDA Center for Biologics Evaluation and Research for regulatory guidance. The application deadline is June 6th, 2023, with subsequent deadlines in 2024 and 2025. More information can be found on the grants.gov website.
    Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required). This grant aims to support early-career scientists and health professionals interested in transitioning to a small business to gain industry experience, receive entrepreneurial training and mentorship, and advance biomedical or public health technology with commercial potential. The grant utilizes the R43/R44 SBIR Award mechanism and supports research and development efforts, as well as the employment and salaries of researchers as Program Directors/Principal Investigators overseeing the project. The grant requires the inclusion of at least one mentor and a career development plan for the PD/PI, which may include entrepreneurship training. The eligibility of the contact PD/PI is limited to scientists, engineers, and health professionals who are new to research entrepreneurship and have not independently led significant research programs. The proposed projects must pertain to the mission space of one of the participating Institutes and Centers and fall within the scope of the traditional SBIR/STTR grant mechanisms. The grant supports Phase I and Fast-Track applications and encourages diversity in the biomedical entrepreneurial workforce. The specific research priorities and areas of interest vary among the participating Institutes and Centers, such as the National Center for Complementary and Integrative Health, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, and others. The grant is currently open for applications, with multiple application due dates throughout the year. More information and the full solicitation can be found at the provided links.
    Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the late-stage translation of biomedical and behavioral research results in arthritis and musculoskeletal and skin diseases from academic/non-profit labs to the marketplace. This Small Business Innovation Research (SBIR) grant opportunity aims to support the development of diagnostic tools, prevention tools, and treatments for these diseases. The focus is on moving lab technologies towards commercial dissemination through partnerships and close collaboration between small businesses and the original developers of the technologies. The research objectives include late-stage pre-clinical studies on technology or therapy feasibility, as well as studies required for regulatory approval before clinical testing. Clinical trials are excluded from this opportunity. The research topics of interest include the development of therapies, innovative drug delivery strategies, biomarker studies, outcome measures and methodologies, and 3D human tissue models. Collaboration between academic/non-profit labs and small businesses is encouraged, with the academic/non-profit labs performing a portion of the project. The proposal should include milestones with quantitative success criteria to measure the progress and efficacy of the project. Applications that do not originate from academic/non-profit labs or propose intervention studies are not responsive to this opportunity. The grant is open for applications until September 6, 2025. For more information, visit the solicitation agency URL: link.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The purpose of this funding opportunity is to support small business concerns in developing technologies for commercialization that can fill the service gaps in addressing SUD. The research objectives include developing products that reduce costs, time, and increase access in addressing health-related social needs such as housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The technologies can include physical devices, digital services, software, or non-physical/non-tangible products. The funding opportunity is open for applications until March 14, 2026, and offers both Phase I and Phase II funding options. Phase I focuses on establishing technical merit and feasibility, while Phase II aims to advance technologies towards commercialization. Applicants are encouraged to review the guidelines and adhere to the requirements applicable to their research.